The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular risk.

Journal of clinical hypertension (Greenwich, Conn.)

Volumn 9, Issue 12 Suppl 5, 2007, Pages 23-30

  Weir, Matthew R ^a   Neutel, Joel M ^a   Bhaumik, Amitabha ^a   De Obaldia, Maria Elena ^a   Lapuerta, Pablo ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BIPHENYL DERIVATIVE; HYDROCHLOROTHIAZIDE; IRBESARTAN; TETRAZOLE DERIVATIVE;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; OBESITY; RISK FACTORS; TETRAZOLES; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 39349086966     PISSN: 15246175     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-6175.2007.07805.x     Document Type: Article

References (0)